key: cord-1050951-3g8asqkb
authors: Shoham, Shmuel; Bloch, Evan M; Casadevall, Arturo; Hanley, Daniel; Lau, Bryan; Gebo, Kelly; Cachay, Edward; Kassaye, Seble G.; Paxton, James H.; Gerber, Jonathan; Levine, Adam C; Naeim, Arash; Currier, Judith; Patel, Bela; Allen, Elizabeth S.; Anjan, Shweta; Appel, Lawrence; Baksh, Sheriza; Blair, Paul W.; Bowen, Anthony; Broderick, Patrick; Caputo, Christopher A; Cluzet, Valerie; Elena, Marie Cordisco; Cruser, Daniel; Ehrhardt, Stephan; Forthal, Donald; Fukuta, Yuriko; Gawad, Amy L.; Gniadek, Thomas; Hammel, Jean; Huaman, Moises A.; Jabs, Douglas A.; Jedlicka, Anne; Karlen, Nicky; Klein, Sabra; Laeyendecker, Oliver; Karen, Lane; McBee, Nichol; Meisenberg, Barry; Merlo, Christian; Mosnaim, Giselle; Park, Han-Sol; Pekosz, Andrew; Petrini, Joann; Rausch, William; Shade, David M.; Shapiro, Janna R.; Singleton, Robinson J.; Sutcliffe, Catherine; Thomas, David L.; Yarava, Anusha; Zand, Martin; Zenilman, Jonathan M.; Tobian, Aaron A.R.; Sullivan, David J.
title: Transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection: a double-blinded, phase 2 randomized, controlled trial
date: 2022-05-17
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac372
sha: 8196283366516c4c9ac3c51a55bf225d0871c83b
doc_id: 1050951
cord_uid: 3g8asqkb

BACKGROUND: The efficacy of SARS-CoV-2 convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection. METHODS: This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed COVID-19 in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was new SARS-CoV-2 infection. RESULTS: 180 participants were enrolled; 87 were assigned to CCP and 93 to control plasma, and 170 transfused at 19 sites across the United States from June 2020 to March 2021. Two were excluded for screening SARS-CoV-2 RT-PCR positivity. Of the remaining 168 participants, 12/81 (14·8%) CCP and 13/87 (14·9%) control recipients developed SARS-CoV-2 infection; 6 (7·4%) CCP and 7 (8%) control recipients developed COVID-19 (infection with symptoms). There were no COVID-19-related hospitalizations in CCP and 2 in control recipients. Efficacy by restricted mean infection free time (RMIFT) by 28 days for all SARS-CoV-2 infections (25·3 vs. 25·2 days; p = 0·49) and COVID-19 (26·3 vs. 25·9 days; p = 0·35) was similar for both groups. CONCLUSIONS: Administration of high-titer CCP as post-exposure prophylaxis, while appearing safe, did not prevent SARS-CoV-2 infection.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for Coronavirus Disease 2019 (COVID- 19) 2 and the pandemic that has claimed millions of lives [1] . Especially at the pandemic's onset, effective preventive 3 strategies were limited. Even by 2022, many have not been vaccinated, and some do not respond to vaccination [2, 3]. 4

The urgency of effective prevention is highest within households of SARS-CoV-2 infected persons since 10-50% will be 5 secondarily infected. Passive immunotherapy using preformed antibodies is effective as post-exposure prophylaxis (PEP) 6 against many infections [4] [5] [6] [7] . Combinations of monoclonal antibodies (mAb) are effective as COVID 9] . 7 COVID-19 convalescent plasma (CCP) may confer protection during early infection and in those without antibodies [10-8 12] . CCP has some advantages over mAb's, including ease of procurement, low cost, and resilience against viral variants 9

[13]. This study sought to evaluate the safety and efficacy of CCP containing anti-SARS-CoV-2 antibodies as PEP. 10

Study design and Participants 12 A randomized, double-blind, placebo-controlled clinical trial was conducted to compare the safety and efficacy of 13 transfusion of CCP (intervention) with SARS-CoV-2 non-immune control plasma. 14 Asymptomatic participants aged ≥18 years who had a close contact exposure to a person with confirmed COVID-19 in 15 the previous 120 hours and did not have SARS-CoV-2 vaccination, and past or active SARS-CoV-2 infection were eligible. 16

The applied definition of close contact exposure was that used by Centers for Disease Control and Prevention (CDC) 17 during the study period. Transfused participants positive by RT-PCR at screening were excluded from analyses. 18

Participants were enrolled at 19 US centers between June 11, 2020 to June 23, 2021. Approval was obtained from the 19 Institutional Review Boards at Johns Hopkins University School of Medicine functioning as single IRB for all participating 20 sites. The protocol was additionally approved by the Department of Defense (DoD) Human Research Protection Office. 21

An independent data and safety monitoring board provided oversight and reviewed efficacy and safety as the study was 22 conducted. All participants provided written informed consent. Nasal swabs were collected at screening (days -1 to 0) and at days 1, 7, 14, and 28. Assessments for COVID-19 37

(symptomatic infection) were conducted at screening, transfusion, and days 1, 3, 7, 14, 28, and 60. Safety assessments 1 were continued to day 90. Viral testing was performed using RT-PCR that targeted the SARS-CoV-2 nucleocapsid gene. 2

Recipient antibody levels were measured by RBD endpoint titers. 3

The primary efficacy outcome was incident SARS-CoV-2 infection by study day 28 by positive RT-PCR testing conducted 5 on collected nasal swabs or by clinical RT-PCR testing conducted outside the study. 6

Secondary efficacy outcomes 7

Disease severity was measured to day 28 using a clinical event scale (supplementary material) and evaluated using an 8 ordinal logistic model. Efficacy for preventing SARS-CoV-2 infection and COVID-19 was examined based on donor 9

antibody titer through characterization of donor IgG, including end point titers and area under the curve (AUC) using a 10 standardized ELISA to measure IgG against the spike and receptor binding proteins and anti-SARS-CoV-2 IgG against 11 recombinant S1 domain of the SARS-CoV-2 spike protein (Euroimmun) as previously described [14] . 12

The Common Terminology Criteria for Adverse Events (CTCAE) 5·0 was used for grading of adverse events (AE). The 14 safety outcomes were monitored throughout the study, including transfusion-related serious AEs (SAEs) (i.e. severe 15 transfusion reactions, acute respiratory distress syndrome and grade 3 or 4 adverse events). The masked independent 16 medical monitor evaluated AEs, SAEs and changes in baseline safety laboratory values. 17

The pre-specified primary analysis of cumulative SARS-CoV-2 infection was conducted using a time-to-event analysis to 19 compare the restricted mean survival time, referred to henceforth as restricted mean infection free time (RMIFT). 20

We calculated and compared the restricted mean survival times by 28 days and risk difference (RD) by treatment arm in 21 a modified intention to treat (mITT) analysis. We performed the primary analysis according to the participants' original 22 randomized treatment groups excluding those who did not receive a transfusion of study plasma and those who were 

A pre-specified sensitivity analysis was restricted to participants who remained infection-free up to day 4 to account for 1 people with early and still undetectable infection when CCP was administered and for an expected lag between 2 transfusion and effect from passive antibody transfer. Since protocolized RT-PCR testing was not performed on days 2 3 and 3, it is possible that infected asymptomatic patients were included in this analysis. 4

Analysis for donor spike antibody titer was conducted for AUC as a continuous variable: controls were assigned a value 6 of zero. To model antibody effect, a flexible Weibull time to event model was used[18] to estimate the hazard ratios. To 7 allow for non-linearity, both natural cubic splines and fractional polynomials were assessed choosing the model with the 8 lowest Akaike Information Criterion (AIC) [19] . Data on days from donation to transfusion were collected and compared 9

in the CCP vs placebo group. 10

Safety 11

Rates of severe transfusion reactions, AEs, grade 3 or 4 AEs, and death were evaluated by treatment arm; 95% 12 confidence intervals (CI) were calculated using skewness-corrected asymptotic score for exact CI[20], using the R 13

package 'ratesci'. 14

The trial did not meet the target sample of 500 participants as enrollment stopped with widespread vaccine availability. 16 The sample size calculation is provided as supplementary material. A conditional power analysis, using the R package 17 'gsDesign', was conducted to assess the likelihood of providing evidence for the efficacy of convalescent plasma. 18

Of 1,138 participants screened, 180 (15·8%) were eligible and consented to the study and 170 were transfused (82 CCP; 20 88 control plasma; Figure 1 ). Of those transfused, two were excluded from efficacy analyses for baseline SARS-CoV-2 21

RT-PCR positivity. Table 1 lists participants' demographic and baseline characteristics. Median time from exposure to 22 transfusion was 2 days (IQR 1-4). Seven participants (3 CCP recipients) did not complete all study components. 23 CCP from 70 unique donations was transfused to 82 recipients; the IgG inverse endpoint titers to protein S were > 1,000 24 except for a single unit at 540. More than 85% of the plasma units were hospital qualified EUA high titer by Euroimmun 25

Arbitrary units >3·5, international spike binding arbitrary units/mL > 60, RBD AUC>900 and virus 3-day culture 26 neutralization > 8 International units/mL (appendix Figure S1 ). 27

Of the 168 participants in the mITT analyses, 12/81 (14·8%) CCP and 13/87 (14·9%) control recipients tested positive for 29 SARS-CoV-2 RNA. Three were positive on day 1 post-transfusion and 3 on days 2-3. The RMIFT by 28 days was 25·3 days 30

for CCP and 25·2 for control recipients (p=0·47. The RD was 0·01 (p=0·42) lower for CCP. Excluding infections through 31 day 3, the RMIFT was 26·6 days for CCP and 25·8 for control recipients (p=0·15). The RD was 0·04 (p=0·21) lower for CCP. 32

Six (7·4%) CCP and 7 (8%) control recipients had COVID-19 (4 and 5 after day 3 from transfusion). The RMIFT by 28 days 33

was 26·3 for the CCP and 25·9 days for the control recipients. The RD between groups was 0·012 lower for CCP. 34

Excluding infections through day 3, the CCP group was consistently, but not significantly, better than control (difference 35

in RMIFT =0·7 days, p=0·14; RD=0·017). Cumulative incidence of confirmed SARS-CoV-2 infections and of COVID-19, 36

using a time-to-event analysis to compare the restricted mean survival (infection free) time are shown in figures 2 and 3. 37

Conditional power analyses were conducted since the target enrollment (500 transfused) was not reached. Had target 1 enrollment been reached it is unlikely that statistically significant results would have been achieved, with chances for 2 significant differences in RMIFT and RD calculated as 0·3% and 0·6% respectively. 3

There were 86 reported AEs, of which 28 occurred with CCP and 58 with control plasma; 17/86 events were grade 3 or 4 5

Five participants required hospitalization (2 for COVID-19) all with control plasma (Supplemental Materials). CCP 6 recipients had a lower proportion of any AEs (p=0·005), and severe AEs (p=0·06) ( Table 2) . 7

Clinical Severity Score 8 Two control participants required hospitalizations for COVID-19 (Table 3 ). The distribution of clinical severity was similar 9

between the two groups for all events after transfusion (OR 0·99) and for events >3 days after transfusion (OR 0·94). 10

The donor antibody levels measured by binding to SARS-CoV-2 proteins or by virus neutralizations as well as the interval 12 from plasma donation to transfusion was comparable in those infected or not infected when limiting analysis to those 13 developing infection > 3 days after transfusion (Supplemental Figure 1 and 2) . Pharmacokinetic analysis on 24 14

participants showed recipient antibody levels to be 4% or a 25-fold reduction from donor antibody levels with a 7-day 15 recipient half-life measured over 14 days (Figure 4) . 16

This randomized, placebo-controlled, double-blinded trial evaluated the efficacy and safety of a unit of high antibody 18

titer CCP for prevention of SARS-CoV-2 infection following recent, close contact exposure to a person with COVID-19. In 19 this sample of outpatients, CCP did not reduce SARS-CoV-2 infection in participants transfused up to 120 hours following 20 exposure. 21

The findings contrast with successful use of mAbs for PEP [8] . Inability of CCP to prevent infection cannot be ascribed to 22 the absence of specific antibody to SARS-CoV-2, as both CCP and mAbs contain SARS-CoV-2 specific antibodies. 23

Insufficient antibody dose in the CCP used is one explanation for lack of efficacy as PEP. The amount of immunoglobulin 24 in the casirivimab/imdevimab dose is 12 grams, likely exceeding the amount of viral-specific antibodies in a unit of high-25 titer plasma. The concentration of antibodies in the casirivimab/imdevimab PEP trial was 22-25 mg/L which is about 150 26 times that needed for neutralization of many variants [21, 22] . CCP used in this study had geomean neutralizing 27 international units/mL of 1:27, which when diluted about 30-fold after transfusion, resulted in 10-100 lower neutralizing 28 capacity than mAbs. Neutralization potency of CCP may be impacted by multiple factors including time of plasma 29 collection, distance from location of use, severity of illness and age. The impact of viral variants on efficacy of plasma 30 collected earlier in the pandemic may be most profound with variants such as delta and omicron. Those would not have 31

impacted the results of this trial. It is possible that low levels of the delta variant were present at the clinical sites during 32 this trial, however, the treatment phase was completed prior to widespread circulation of those variants in the US. 33

Qualitative differences between the products could also affect efficacy. For CCP, much of the neutralizing capacity is in 34

IgM [23], a large molecule with poor tissue penetration; mAbs are entirely IgG, which has better tissue penetration [24] . 35

Breakthrough SARS-CoV-2 infections despite vaccination provide insight as to why CCP did not prevent infection. Serum 36

IgG is unlikely to prevent upper airways infection, presumably because of insufficient concentration within respiratory 37 airway mucosa during initial infection when the epithelium is intact. As infection progresses an inflammatory response 38

permits transudation of serum (and IgG) into tissues. Our results contrast with those of a study using the same plasma 1 supply, which found that CCP administered early in COVID-19 reduced hospitalization by 54% [25] . The large amount of 2 immunoglobulin in plasma after prophylactic mAb administration or vaccination is presumably sufficient to prevent 3 progression of infection to severe disease. However, the amount of specific antibody after a unit of CCP may be 4 insufficient to affect the course of initial infection, especially if much of the neutralizing antibody is IgM. This is 5 consistent with animal studies reporting antibodies' inefficiency at reducing virus in nasal tissues [26] . Notably, two 6 control participants were hospitalized for COVID-19 (one with hematological disease and hypogammaglobulinemia). 7

Though the numbers are small, none of those who received CCP progressed to hospitalization, which is consistent with 8 findings that early treatment with passive immunotherapy (CCP or mAbs) reduces disease progression [10]. 9

Our study affords insight into the optimal timing of CCP administration. Although numerous clinical trials and 10 observational studies were initiated early in the pandemic, these - The study had limitations. The logistical challenges were formidable and frequently changed with the evolving pandemic. 36

Enrollment declined precipitously with widespread vaccine availability. Previously vaccinated individuals were ineligible 37

for participation, and guidance to defer vaccination until 90 days after receipt of CCP deterred potential subjects. The 38 enrollment goal of 500 total participants was not achieved. However, conditional power analyses for the primary 39 endpoint of infection suggest that results may not have significantly differed had the trial achieved target enrollment. 40

In conclusion, this RCT of high titer CCP given to participants exposed to, but not infected with SARS-CoV-2, within 120 1 hours demonstrated that CCP did not provide evidence of efficacy. Acknowledging the challenges of enrollment in the 2 setting of vaccine availability, the ongoing evolution of SARS- CoV-2 with loss of multiple treatment and prevention  3 options, could renew interest in new studies of CCP as PEP. Such studies should consider a higher dose of antibodies 4 (i.e., collected from donors who have a history of SARS-CoV-2 infection and have also previously been vaccinated) 5

and/or transfusion with multiple CCP units. Further, studies would best target populations most at risk, including the 6 immunocompromised or elderly, with greater emphasis on clinical rather than laboratory outcomes. 7 NOTES 8

Supplementary materials are available at Clinical Infectious Diseases online. 10

Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the 11 sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. 12 13

The authors gratefully acknowledge the study participants who generously gave of their time and biological specimens. Foundation. The study sponsors did not contribute to the study design; the collection, analysis, and interpretation of 23 data; manuscript preparation, and the decision to submit the paper for publication. 24

The authors report-KG-grants or contracts unrelated to this work and paid to institution from NIHI, personal fees from 26

Aspen Center for Advancing Translational Sciences (NCATS) U24TR001609-S3. All other authors report no relevant disclosures. (n=24) who were seronegative at screening and who did not acquire infection were measured for RBD 12 protein antibody area under the curve (AUC) levels at day 1 (n=24), 7 (n=21) and 14 (n=20) after 13 infection. Geometric means are shown. The recipient day 1 RBD levels were 4% of donor plasma levels. 14 The half-life over days 1-14 is 7 days, half-life from day 1-7 is 4·5 days and over day 7 to 14 is 11·3 days. 

WHO. WHO (COVID-19) Homepage. Available at

COVID-19) Vaccinations

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid 5 Organ Transplant Recipients

Use of Convalescent Measles Serum to Control Measles in a Preparatory School

MUMPS: Use of Convalescent Serum in the Treatment and Prophylaxis of Orchitis

Hark back: passive immunotherapy for 11 influenza and other serious infections

Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-15 19

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among 17 Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older 20 Adults

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-22 19

Association of Convalescent Plasma Therapy With Survival in 24 Patients With Hematologic Cancers and COVID-19

SARS-CoV-2 variants and convalescent plasma: reality, 26 fallacies, and opportunities

Sex, age, and hospitalization drive antibody responses in a COVID-19 28 convalescent plasma donor population

Improved precision in the analysis of randomized trials with 30 survival outcomes, without assuming proportional hazards

Improving precision and power in 32 randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes

Enhanced precision in the analysis of randomized trials with ordinal 35 outcomes

Flexible parametric proportional-hazards and proportional-odds models for censored 1 survival data, with application to prognostic modelling and estimation of treatment effects

Model selection for univariable fractional polynomials

REGEN-COV Antibody Combination and Outcomes in 6 Outpatients with Covid-19

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 8 mutational escape in preclinical and human studies

Major role of IgM in the neutralizing activity of convalescent plasma 10 against SARS-CoV-2

Immunoglobulins in the lung

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with 13 High-Titer Convalescent Plasma

Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic 15 neutralizing antibodies

Convalescent plasma or hyperimmune immunoglobulin for people with 17 COVID-19: a living systematic review

Early Convalescent Plasma for High-Risk Outpatients with Covid-19

COVID-19 convalescent plasma: Interim recommendations from the 21 AABB

Exploratory efficacy endpoints in 23 the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Antibody-dependent enhancement and COVID-19: Moving toward acquittal

COVID-19 Convalescent Plasma: Now Is the Time for Better Science

Early safety indicators of COVID-19 convalescent plasma in 5000 29 patients

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized 31 Patients